[8-K] Bone Biologics Corp Warrants Reports Material Event

Rhea-AI Filing Summary

Bone Biologics (Nasdaq: BBLG / BBLGW) filed an 8-K (Item 8.01) reporting that Nasdaq’s Listing Qualifications Department confirmed on June 25 2025 the company has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share. The confirmation removes the prior deficiency notice and the immediate risk of delisting from the Nasdaq Capital Market.

The disclosure, delivered via a press release furnished as Exhibit 99.1, contains no additional financial data, share issuances, or operational updates. By maintaining its listing, the company preserves liquidity, institutional access, and market visibility—factors critical to future capital-raising efforts.

Positive

• Regained compliance with Nasdaq Listing Rule 5550(a)(2), removing immediate delisting risk and preserving market liquidity.

Negative

• None.

Insights

Risk Analyst

TL;DR: Delisting threat gone—governance risk drops, fundamentals unchanged.

Nasdaq’s confirmation that Bone Biologics has met the $1 bid price threshold eliminates a potentially value-destroying delisting scenario. Continued access to the Nasdaq Capital Market safeguards trading liquidity, institutional ownership eligibility, and index inclusion prospects. While this is an unequivocal governance positive, the filing offers no insight into the durability of the share-price recovery or underlying business performance. Investors should still monitor volatility; another 30-day bid-price slip could restart the deficiency clock. Near-term financing risk also remains, but today’s news meaningfully reduces systemic listing-status uncertainty.

false 0001419554 0001419554 2025-06-25 2025-06-25 0001419554 BBLG:CommonStockParValue0.001PerShareMember 2025-06-25 2025-06-25 0001419554 BBLG:WarrantsToPurchaseCommonStockParValue0.001PerShareMember 2025-06-25 2025-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-40899		42-1743430
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
2 Burlington Woods Drive, Ste. 100 Burlington, MA				01803
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (781) 552-4452

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		BBLG		Nasdaq Capital Market
Warrants to Purchase Common Stock, par value $0.001 per share		BBLGW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 26, 2025, Bone Biologics Corporation (the “Company”) issued a press release announcing that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 25, 2025, confirming that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated June 26, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BONE BIOLOGICS CORPORATION
Date: June 26, 2025
	By:	/s/ Jeffrey Frelick
		Jeffrey Frelick
		Chief Executive Officer

FAQ

When did [[BBLGW]] regain compliance with Nasdaq’s minimum bid price rule?

Nasdaq issued a confirmation letter on June 25 2025 stating the company is again in compliance with Listing Rule 5550(a)(2).

What Nasdaq rule is referenced in Bone Biologics’ 8-K filing?

The filing cites Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share.

Did the company execute a reverse split to regain compliance?

No. The 8-K indicates compliance was achieved without disclosing any reverse split or other corporate action.

Why is bid-price compliance important for [[BBLGW]] investors?

Maintaining compliance avoids delisting, thereby preserving trading liquidity and visibility on the Nasdaq Capital Market.

What exhibits accompany this Form 8-K?

Exhibit 99.1 is the June 26 2025 press release; Exhibit 104 is the cover-page Inline XBRL data file.